Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
24,604 Shares in Novo Nordisk A/S $NVO Purchased by Runnymede Capital Advisors Inc.
06:59am, Monday, 06'th Apr 2026
Runnymede Capital Advisors Inc. purchased a new stake in Novo Nordisk A/S (NYSE: NVO) in the undefined quarter, according to its most recent filing with the SEC. The fund purchased 24,604 shares of th
Why Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market
05:02pm, Friday, 03'rd Apr 2026
The market for weight loss drugs still has plenty of room to grow. Novo Nordisk's new subscription model for Wegovy could help expand its reach.
Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts
12:10pm, Friday, 03'rd Apr 2026
One of the world's leading healthcare names, Novo Nordisk (NYSE:NVO) cut prices on Wegovy and Ozempic by up to 48% in India at the start of April 2026, a direct response to low-cost generic semaglutid
Novo Nordisk A/S $NVO Shares Sold by Eldred Rock Partners LLC
04:45am, Friday, 03'rd Apr 2026
Eldred Rock Partners LLC trimmed its stake in Novo Nordisk A/S (NYSE: NVO) by 10.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund
Novo Nordisk A/S $NVO Stock Position Lifted by Banque Pictet & Cie SA
03:30am, Friday, 03'rd Apr 2026
Banque Pictet and Cie SA grew its holdings in shares of Novo Nordisk A/S (NYSE: NVO) by 68.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 86,64
Novo Nordisk (NVO) Rises Higher Than Market: Key Facts
06:45pm, Thursday, 02'nd Apr 2026
Novo Nordisk (NVO) closed at $36.98 in the latest trading session, marking a +1.37% move from the prior day.
Trump Administration Unveils Up to 100% Tariff on Branded Drugs
05:34pm, Thursday, 02'nd Apr 2026
Drugmakers or countries that strike pricing deals or make manufacturing investment commitments in the U.S. can secure much lower levies, or none at all.
Novo Nordisk: Competing In A Duopoly
05:13pm, Thursday, 02'nd Apr 2026
Novo Nordisk A/S (NVO) faces intense competition from Eli Lilly in the fast-growing GLP-1 market, impacting its growth outlook and valuation. NVO's future growth hinges on defending market share with
71 April Graham Value All-Stars (GVAS): 14 To Buy
02:33pm, Thursday, 02'nd Apr 2026
The April 2026 GASV list highlights 14 fair-priced, 'safer' mid-to-large-cap value stocks with strong dividend profiles and positive free-cash-flow-yields. Top ten GASV stocks are projected to deliver
Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
11:14am, Thursday, 02'nd Apr 2026
The Trump administration is preparing to impose new tariffs on branded drugs from pharmaceutical companies that have not struck landmark deals with the president to lower their U.S. drug prices, CNBC
GLP-1 wars: Lilly's FDA-approved oral weight-loss pill puts Novo Nordisk's Wegovy franchise under fresh pressure
09:12am, Thursday, 02'nd Apr 2026
Foundayo launches on April 6 at the same price as Novo's pill, threatening to reshape the $50 billion obesity drug market before Novo's first-quarter...
GLP-1 wars: Lilly's FDA-approved oral weight-loss pill puts Novo Nordisk's Wegovy franchise under fresh pressure
08:20am, Thursday, 02'nd Apr 2026
Foundayo launches on April 6 at the same price as Novo's pill, threatening to reshape the $50 billion obesity drug market before Novo's first-quarter results Eli Lilly and Co (NYSE:LLY) has won FDA ap
Novo Nordisk says Wegovy pill outperforms Lilly's oral GLP-1 in cross-trial comparison
08:00am, Thursday, 02'nd Apr 2026
Oral Wegovy demonstrated "significantly greater mean weight loss" than Lilly's rival pill Foundayo, which was approved this week, Novo Nordisk said Thursday. Novo's findings evaluated previously publi
Wall Street sees multi-billion dollar debut for Lilly's obesity pill despite Novo lead
07:28am, Thursday, 02'nd Apr 2026
Eli Lilly's newly approved weight-loss pill is expected to generate billions in sales as soon as this year, with analysts betting it will quickly narrow Novo Nordisk's head start in the oral market
Novo Nordisk shares resilient as FDA approves Eli Lilly GLP-1 weight-loss pill to intensify competition
03:12am, Thursday, 02'nd Apr 2026
Shares in Novo Nordisk (NYSE:NVO) held firm and edged higher in early trading on Thursday despite the US Food and Drug Administration approving a new once-daily weight-loss pill from rival Eli Lilly t
